Skip to main content

SLN Silence Therapeutics plc

Healthcare

8.87

Close 10/13

Open
9.53
High
9.57
Low
8.71
Prev close
9.65
Volume
1.5M
52W 4.19 17.58
Loading candles…

Is Silence Therapeutics plc a buy? Fundamentals and valuation first

As of 2026-10-13

Every dimension sits in the neutral range.

Momentum Neutral 240-day return is Good, but 60-day return is Average.
60-day return (%) -15.44 28th percentile Average
240-day return (%) 21.34 74th percentile Good
Risk / liquidity Neutral 20-day dollar volume is Good, but 60-day annualized volatility is Average.
20-day dollar volume 10,422,937 65th percentile Good
60-day annualized volatility (%) 85.79 78th percentile Average

Silence Therapeutics plc (SLN) today

1 quant signals active · As of 2026-10-13

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Silence Therapeutics plc (SLN) peers and tracking

Watchlist

This page refreshes daily after the close. Add Silence Therapeutics plc to your watchlist to track signal changes on your next visit.

Silence Therapeutics plc (SLN) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 88.88%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

12 historical occurrences (since 2021-05-07)
Average forward return after Top-quintile 6-month momentum。20-day: Win 50%, Sample 12, Median -0.24%, Excess +3.33%, Beat mkt rate 50%；60-day: Win 33.3%, Sample 12, Median -2.69%, Excess +2.87%, Beat mkt rate 33.3%；120-day: Win 36.4%, Sample 11, Median -11.7%, Excess +4.01%, Beat mkt rate 36.4%

120 days after: historical avg +15.4%

20-day +5.51%
60-day +8.78%
120-day +15.4%
20-day
60-day
120-day
Win
50%
33.3%
36.4%
Sample
12
12
11
Median
-0.24%
-2.69%
-11.7%
Excess
+3.33%
+2.87%
+4.01%
Beat mkt rate
50%
33.3%
36.4%

Over 11 occurrences, 120-day forward avg gained 15.4%, beat the market by 4.01 pts; win rate 36.4%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 98,272 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.50%, a 58.4% positive-return rate, and +3.15 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

Continue researching Silence Therapeutics plc with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.
  • This is an American depositary receipt (ADR). The data does not say how many ordinary shares each ADR represents, so per-share and market-value metrics (P/E, price/book, free-cash-flow yield, EPS growth and earnings surprises) are not computed.
  • ADRs listed on NYSE or NASDAQ are covered as a separate group selected by dollar volume, in addition to the common-stock universe; the 6-month momentum signal ranks each ADR against the liquid US common stocks.
  • The company has reported its financial statements in more than one currency, so margins, growth and valuation figures that would combine them are not computed.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.